Degree of tumor FDG uptake correlates with proliferation index in triple negative breast cancer

Molecular Imaging and Biology

Volumn 12, Issue 6, 2010, Pages 657-662

  Tchou, Julia ^a,b   Sonnad, Seema S ^a,b   Bergey, Meredith R ^b   Basu, Sandip ^b,c   Tomaszewski, John ^b   Alavi, Abass ^b   Schnall, Mitchell ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c TATA MEMORIAL HOSPITAL   (India)

Author keywords

Breast cancer; FDG; Ki67; PET; Proliferation index; SUV; Triple negative breast cancer

Indexed keywords

FLUORODEOXYGLUCOSE F 18; KI 67 ANTIGEN;

ADULT; ARTICLE; BREAST CANCER; CANCER GRADING; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; DISEASE SEVERITY; DRUG UPTAKE; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE; TUMOR DIFFERENTIATION; TUMOR VOLUME; WHOLE BODY PET;

ADULT; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CELL PROLIFERATION; FEMALE; FLUORODEOXYGLUCOSE F18; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MIDDLE AGED; MITOTIC INDEX; PILOT PROJECTS; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RETROSPECTIVE STUDIES;

EID: 78650513640     PISSN: 15361632     EISSN: 18602002     Source Type: Journal    
DOI: 10.1007/s11307-009-0294-0     Document Type: Article

References (19)

1. M Dowsett IE Smith SR Ebbs JM Dixon A Skene R A'Hern J Salter S Detre M Hills G Walsh 2007 Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer J Natl Cancer Inst 99 2 167 170 1:CAS:528:DC%2BD2sXhvVOhtbc%3D 10.1093/jnci/djk020 17228000 (Pubitemid 47232611)
2. M Dowsett IE Smith SR Ebbs JM Dixon A Skene C Griffith I Boeddinghaus J Salter S Detre M Hills, et al. 2006 Proliferation and apoptosis as markers of benefit in neoadjuvant endocrine therapy of breast cancer Clin Cancer Res 12 3 Pt 2 1024s 1030s 1:CAS:528:DC%2BD28XhtFeitL0%3D 10.1158/1078-0432.CCR-05-2127 16467120 (Pubitemid 43259839)
3. G von Minckwitz S Kummel P Vogel C Hanusch H Eidtmann J Hilfrich B Gerber J Huober SD Costa, et al. 2008 Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial J Natl Cancer Inst 100 8 542 551 10.1093/jnci/djn085
4. P Rastogi SJ Anderson HD Bear CE Geyer MS Kahlenberg A Robidoux RG Margolese JL Hoehn VG Vogel, et al. 2008 Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27 J Clin Oncol 26 5 778 785 10.1200/JCO.2007.15.0235 18258986 (Pubitemid 351264391)
5. N Avril CA Rose M Schelling J Dose W Kuhn S Bense W Weber S Ziegler H Graeff M Schwaiger 2000 Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations J Clin Oncol 18 20 3495 3502 1:STN:280:DC%2BD3M%2Fhsl2hsA%3D%3D 11032590
6. W Shimoda M Hayashi K Murakami T Oyama M Sunagawa 2007 The relationship between FDG uptake in PET scans and biological behavior in breast cancer Breast Cancer 14 3 260 268 10.2325/jbcs.14.260 17690502
7. K Higashi AC Clavo RL Wahl 1993 In vitro assessment of 2-fluoro-2-deoxy-D-glucose, L-methionine and thymidine as agents to monitor the early response of a human adenocarcinoma cell line to radiotherapy J Nucl Med 34 5 773 779 1:CAS:528:DyaK3sXltlCmt78%3D 8478710 (Pubitemid 23141556)
8. S Basu W Chen J Tchou A Mavi T Cermik B Czerniecki M Schnall A Alavi 2008 Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization Cancer 112 5 995 1000 1:CAS:528:DC%2BD1cXjs1eqsLo%3D 10.1002/cncr.23226 18098228 (Pubitemid 351304582)
9. EA Rakha JS Reis-Filho IO Ellis 2008 Basal-like breast cancer: a critical review J Clin Oncol 26 15 2568 2581 10.1200/JCO.2007.13.1748 18487574
10. J Tchou LP Wang M Sargen S Sonnad J Tomaszewski M Schnall 2006 Do triple-negative breast cancers have a distinct imaging phenotype? Breast Cancer Res Treat 100 Supplement 1 S128
11. CM Perou T Sorlie MB Eisen M van de Rijn SS Jeffrey CA Rees JR Pollack DT Ross H Johnsen, et al. 2000 Molecular portraits of human breast tumours Nature 406 6797 747 752 1:CAS:528:DC%2BD3cXmt1CnsLw%3D 10.1038/35021093 10963602
12. T Sorlie CM Perou R Tibshirani T Aas S Geisler H Johnsen T Hastie MB Eisen M van de Rijn, et al. 2001 Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications Proc Natl Acad Sci USA 98 19 10869 10874 1:CAS:528:DC%2BD3MXntVGmsbo%3D 10.1073/pnas.191367098 11553815 (Pubitemid 32878711)
13. RL Wahl K Zasadny M Helvie GD Hutchins B Weber R Cody 1993 Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation J Clin Oncol 11 11 2101 2111 1:STN:280: DyaK2c%2FksFyisQ%3D%3D 8229124 (Pubitemid 23332245)
14. T Jansson JE Westlin H Ahlstrom A Lilja B Langstrom J Bergh 1995 Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer: a method for early therapy evaluation? J Clin Oncol 13 6 1470 1477 1:STN:280:DyaK2M3ntFaksA%3D%3D 7751894
15. M Schelling N Avril J Nahrig W Kuhn W Romer D Sattler M Werner J Dose F Janicke, et al. 2000 Positron emission tomography using [(18)F] Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer J Clin Oncol 18 8 1689 1695 1:STN:280:DC%2BD3c3islyjsw%3D%3D 10764429 (Pubitemid 30220547)
16. J Dose Schwarz M Bader L Jenicke G Hemminger F Janicke N Avril 2005 Early prediction of response to chemotherapy in metastatic breast cancer using sequential 18F-FDG PET J Nucl Med 46 7 1144 1150 16000283 (Pubitemid 43741076)
17. C Rousseau A Devillers C Sagan L Ferrer B Bridji L Campion M Ricaud E Bourbouloux I Doutriaux, et al. 2006 Monitoring of early response to neoadjuvant chemotherapy in stage II and III breast cancer by [18F]fluorodeoxyglucose positron emission tomography J Clin Oncol 24 34 5366 5372 10.1200/JCO.2006.05. 7406 17088570 (Pubitemid 46623167)
18. J Schwarz-Dose M Untch R Tiling S Sassen S Mahner S Kahlert N Harbeck A Lebeau W Brenner, et al. 2009 Monitoring primary systemic therapy of large and locally advanced breast cancer by using sequential positron emission tomography imaging with [18F]fluorodeoxyglucose J Clin Oncol 27 4 535 541 10.1200/JCO.2008.17.2650 19075273
19. G Gasparini S Dal Fior F Pozza P Bevilacqua 1989 Correlation of growth fraction by Ki-67 immunohistochemistry with histologic factors and hormone receptors in operable breast carcinoma Breast Cancer Res Treat 14 3 329 336 1:STN:280:DyaK3c7itlahtg%3D%3D 10.1007/BF01806305 2482095 (Pubitemid 20053763)